- Gliquidone Alleviates Diabetic Nephropathy by Inhibiting Notch/Snail Signaling Pathway. [Journal Article]
- CPCell Physiol Biochem 2018 Dec 06; 51(5):2085-2097
- CONCLUSIONS: Taken together, our results suggested that gliquidone can ameliorate the diabetic symptoms of diabetic nephropathy through inhibiting Notch / Snail1 signaling pathway, improving anti -oxidative response and delaying renal interstitial fibrosis. The efficacy of gliquidone is dose-dependent.
- Sestrin 2 Attenuates Rat Hepatic Stellate Cell (HSC) Activation and Liver Fibrosis via an mTOR/AMPK-Dependent Mechanism. [Journal Article]
- CPCell Physiol Biochem 2018 Dec 06; 51(5):2111-2122
- CONCLUSIONS: Our findings indicate that Sestrin 2 may attenuate the activation of HSCs and ameliorate liver fibrosis, most likely via upregulation of AMPK phosphorylation and suppression of the mTOR signaling pathway.
- Impairment of the antifibrotic prostaglandin E2 pathway may influence neutrophil extracellular traps-induced fibrosis in the mare endometrium. [Journal Article]
- DADomest Anim Endocrinol 2018 Nov 03; 67:1-10
- Prostaglandin E2 (PGE2) has contradictory effects in many organs. It may have proinflammatory, anti-inflammatory, or anti-fibrotic roles, depending on the type of receptors to which it binds. By sign...
Prostaglandin E2 (PGE2) has contradictory effects in many organs. It may have proinflammatory, anti-inflammatory, or anti-fibrotic roles, depending on the type of receptors to which it binds. By signaling through its receptors EP2 and EP4, PGE2 mediates anti-inflammatory and anti-fibrotic actions. In spite of chronic endometrial fibrosis (endometrosis) being a major cause of mare infertility, its pathogenesis is not fully understood. We have shown that contact of mare endometrium in vitro with neutrophil extracellular traps (NETs) proteases favors endometrial collagen type I production. Therefore, we investigated the involvement of the PGE2 pathway in collagen deposition in mare endometrium, challenged in vitro with proteases present in NETs. Mare endometria (Kenney and Doig categories I/IIA and IIB/III), obtained in the follicular phase (FLP) and mid-luteal phase (MLP), were incubated for 24 h with components found in NETs (elastase, cathepsin-G, and myeloperoxidase). Secretion of PGE2 and transcripts for specific PGE synthase (PGES) and PGE2 receptors (EP2 and EP4) were evaluated. Impaired PGE2 production and low EP2 transcript abundance depended on the endometrial category and estrous cycle phase. Impairment of PGE2 and/or EP2 might play a role in FLP (category IIB/III) and MLP (I/IIA) endometrial fibrogenesis because of the reduction in its antifibrotic capacity. In conclusion, priming of the endometrium with endogenous ovarian steroids might inhibit the antifibrotic PGE2 pathway either in healthy or pathologic tissues with collagen formation after NETs proteases action.
- Mulberry leaf polysaccharides suppress renal fibrosis. [Journal Article]
- IJInt J Biol Macromol 2018 Dec 03
- A mulberry leaf polysaccharide (MLP-1) was prepared and partially characterised, and its anti-renal-fibrosis effects were investigated in streptozotocin (STZ)-induced diabetic nephropathy (DN) rats. ...
A mulberry leaf polysaccharide (MLP-1) was prepared and partially characterised, and its anti-renal-fibrosis effects were investigated in streptozotocin (STZ)-induced diabetic nephropathy (DN) rats. MLP-1, with a molecular weight of 2,792,624 Da, consisted of arabinose, glucose, xylose, rhamnose, and mannose in a molar ratio of 1:1.13:2.35:6.74:8.85. Intraperitoneal injection of MLP-1 (2 mL; 0.2-0.4 g/mL) daily for 8 weeks significantly decreased serum insulin, fasting blood glucose, and 24 h urinary albumin, as well as urine protein and connective tissue growth factors, of STZ-induced DN rats. All these results indicated that MLP-1 can effectively inhibit renal fibrosis and potentially treat DN.
- Renoprotective meroterpenoids from the fungus Ganoderma cochlear. [Journal Article]
- FFitoterapia 2018 Dec 03
- Nine multifarious new meroterpenoids, cochlearols E-M (1-9), along with seven known meroterpenoids 10-16, were isolated from the fruiting bodies of Ganoderma cochlear. Racemic 1, 6-8, 10 and 13 were ...
Nine multifarious new meroterpenoids, cochlearols E-M (1-9), along with seven known meroterpenoids 10-16, were isolated from the fruiting bodies of Ganoderma cochlear. Racemic 1, 6-8, 10 and 13 were separated by chiral HPLC. The structures were elucidated based on detailed spectroscopic analyses (HRESIMS, 1D/2D-NMR) and calculated electronic circular dichroism (ECD). Their biological activities against renal fibrosis were evaluated by using rat normal and diseased renal interstitial fibroblast cells (NRK49F). The results show that compounds 7a, 7b, and 10a exhibit potent proliferation inhibition in TGF-β1-induced NRK-49F cells.
- Overexpression of heat shock protein HSP90AA1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: A pilot study. [Journal Article]
- CBClin Biochem 2018 Dec 03
- CONCLUSIONS: TOM34 and its partner HSP90AA1 might be used as a potential biomarker for monitoring HCV-induced HCC progression in the Egyptian population. Future large-scale validation studies are warranted.
- Identification and Modulation of Microenvironment is Crucial for Effective MSC Therapy in Acute Lung Injury. [Journal Article]
- AJAm J Respir Crit Care Med 2018 Dec 06
- CONCLUSIONS: MSCs can be beneficial or detrimental depending on microenvironment at the time of administration. Identification of potential beneficiaries appears to be crucial to guide MSC therapy in ARDS.
- Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. [Review]
- CDCochrane Database Syst Rev 2018 Dec 05; 12:CD009269
- CONCLUSIONS: We found low to very low-quality evidence to suggest that there is no difference in effectiveness between different types of psychosocial interventions to reduce alcohol consumption among people who use illicit drugs, and that brief interventions are not superior to assessment-only or to treatment as usual. No firm conclusions can be made because of the paucity of the data and the low quality of the retrieved studies.
- Vaccines for preventing invasive salmonella infections in people with sickle cell disease. [Review]
- CDCochrane Database Syst Rev 2018 Dec 05; 12:CD006975
- CONCLUSIONS: It is expected that salmonella vaccines may be useful in people with sickle cell disease, especially in resource-poor settings where the majority of those who suffer from the condition are found. Unfortunately, there are no randomized controlled trials on the efficacy and safety of the different types of salmonella vaccines in people with sickle cell disease. We conclude that there is a need for a well-designed, adequately-powered, randomized controlled trial to assess the benefits and risks of the different types of salmonella vaccines as a means of improving survival and decreasing mortality from salmonella infections in people with sickle cell disease. However, we believe that there are unlikely to be any trials published in this area, therefore, this review will no longer be regularly updated.
New Search Next
- Pharmacological interventions for acute hepatitis C infection. [Review]
- CDCochrane Database Syst Rev 2018 Dec 03; 12:CD011644
- CONCLUSIONS: Very low quality evidence suggests that interferon-alpha may decrease the incidence of chronic HCV infection as measured by sustained virological response. However, the clinical impact such as improvement in health-related quality of life, reduction in cirrhosis, decompensated liver disease, and liver transplantation has not been reported. It is also not clear whether this finding is applicable in the current clinical setting dominated by the use of pegylated interferons and direct-acting antivirals, although we found no evidence to support that pegylated interferons or ribavirin or both are effective in people with acute HCV infection. We could find no randomised trials comparing direct-acting antivirals with placebo or other interventions for acute HCV infection. There is significant uncertainty in the benefits and harms of the interventions, and high-quality randomised clinical trials are required.